This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Tor Steensrud Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Steensrud, T. Articles by Sørlie, D. G. Search for Related Content PubMed PubMed Citation Articles by Steensrud, T. Articles by Sørlie, D. G. Related Collections Cardiac - pharmacology Cardiac - physiology Myocardial protection

Clinical testing of nicorandil supplemented normokalemic cardioplegic solution

Department of Cardio-Thoracic and Vascular Surgery, University Hospital of North Norway, Breivika, P.O. Box 102/exp, N-9038 Tromsø, Norway

*Corresponding author. Tel.: +47 77626000; fax: +47 77628298.

E-mail address: tor.steensrud{at}unn.no (T. Steensrud).

Does nicorandil instead of supranormal potassium safely provide cardioplegia and cardioprotection in humans? Fifty patients eligible for coronary artery surgery were randomly divided into two groups; one group received standard St Thomas' Hospital solution (STHS) and the other group got a crystalloid solution in which supranormal potassium was replaced with 0.2 mmol/l nicorandil. We measured time to arrest, rhythm abnormalities, pre- and postoperative troponin-T, CK-MB and myoglobin release as well as hemodynamic parameters. Time to arrest was significantly shorter in the STHS group (41.0±16.8 s) than in the nicorandil group (120.9±78.8 s, P<0.001). Four patients in the nicorandil group needed additional STHS to achieve satisfactory cardiac arrest. Troponin-T was elevated in the nicorandil group at four (P=0.042) and at eight (P=0.044) hours after surgery, myoglobin levels were elevated at 0 h after surgery (P=0.014), CK-MB levels were not group different. Hemodynamic performance was similar in both groups. Potassium should probably not be replaced by nicorandil alone in the cardioplegic solution. This study of low-risk patients with short (43.2 min) aortic cross-clamp times showed similar cardioprotection as revealed by hemodynamic performance whereas early release of troponin-T and myoglobin release in the nicorandil group raised some concern.

Key Words: Cardioplegia; KATP channel opener; Myocardial protection; Potassium